Takeda Pharmaceutical Company Limited
TAK
#433
Rank
$58.218 B
Marketcap
Japan
Country
$18.23
Share price
4.29%
Change (1 day)
23.02%
Change (1 year)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase,…
Key Metrics
Trailing P/E
—
Forward P/E
35.31
EPS (TTM)
$-0.34
Forward EPS
$0.53
Price / Book
1.20
EV / EBITDA
4.1x
Beta
0.10
Dividend Yield
3.31%
Return on Equity
-2.26%
Return on Assets
2.69%
Debt / Equity
73.25
Current Ratio
1.14
Gross Margin
64.47%
Operating Margin
16.45%
Net Profit Margin
-3.54%
Free Cash Flow
$541.444B
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 17 – Sep 15
+7.68%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$27.867B
Latest Net Income$-942,511,684
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Takeda Pharmaceutical Company Limited with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
TAK
No recent news available. Set FINNHUB_API_KEY to enable news.
